Our focus is on consumer healthcare products for sexual healthcare and pain relief management.
The six products in our development pipeline are:
Sexual healthcare |
||
| CSD500 | Launch planning | |
| CSD500 is a CE marked condom that incorporates an erectogenic compound which comes into contact with the penis on application of the condom. | ||
| PET500 | EU - Next milestone: Pivotal clinical trial | |
| USA - Launch planning | ||
| PET500 is a spray for men with premature ejaculation. It contains anaesthetic compounds which reduce sensitivity to help prolong sexual intercourse. | ||
Delivered by  |
||
| MED2002 | Next milestone: Pivotal clinial trial | |
| MED2002 is a topical gel applied directly to the penis for the treatment of male erectile dysfunction. It is expected to be the first OTC treatment for men with erectile dysfunction. | ||
Delivered by  |
||
Pain relief management |
||
| TPR100 | Next milestone: Ongoing development | |
| TPR100 is a product for the provision of topical pain relief. Early clinical work has shown superiority in terms of skin penetration of the active compound compared with the market-leading product. | ||
| Delivered by |
||
| TPR100-Rx | Next milestone: Early stage clincal trial | |
| TPR100-Rx will be a higher strength topical product available on prescription for the treatment of profound indications such as pain associated with osteoarthritis. | ||
| Delivered by |
||
| RAD100 | Next milestone: Early stage clinical trial | |
| RAD100 will be a product which aims to provide rapid local anaesthesia prior to injection, vaccination or cannulation. | ||
| Delivered by |
||